Lite Strategy (LITS)
Manages a Litecoin reserve strategy while retaining two pre-clinical oncology drug assets.
Something off on this page? Send us feedback.
Operates a Litecoin digital-asset treasury through LTC accumulation, covered calls, and possible ecosystem investments. It also retains voruciclib and zandelisib, oncology assets assessed for pre-clinical development, out-licensing, or sale.
Built around a Litecoin digital-asset treasury, the operating model includes LTC accumulation, covered-call yield activity, and possible investments in the Litecoin ecosystem. Digital assets can be transferred as collateral or disposed of as part of that model.
Two retained pharmaceutical assets remain alongside the treasury business: voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral selective PI3Kδ inhibitor. Both are being assessed for pre-clinical work, out-licensing, or sale.
Formerly MEI Pharma, the issuer rebranded in 2025 after adopting Litecoin as its primary reserve asset. The treasury strategy and the two pharmaceutical assets are distinct parts of the current business.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $7.5M · Total debt $0 · Total assets $57.8M · Shareholders' equity $56.8M
- Revenue
- $0
- Operating income
- −$2.8M
- Net income
- −$23.7M
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Nov 16, 2023 | Nov 17 | Dec 6 | $1.75 | special dividend |
| Institutions39 holders · as of Mar 31, 2026 | 17.31% | 5.89M shares | |
| Insiders2 holders · as of Jun 25, 2026 | 11.17% | 3.80M shares | |
| Otherremainder | 71.52% | 24.34M shares |
34.03M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alexander SchornsteinInsider10 percent owner | 10.80% | 3.67M | Form 4filed Dec 22, 2025 ↗ |
Renaissance Technologies LLCInstitution | 5.13% | 1.74M | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 3.07% | 1.04M | 13Fas of Mar 31, 2026 |
Citadel Advisors LLCInstitution | 2.15% | 730,099 | 13Fas of Mar 31, 2026 |
Two Sigma Investments, LPInstitution | 1.81% | 614,442 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 24, 2026 | James P. Flynn | director | +25,000 | $0.8555 |
| Dec 19, 2025 | James P. Flynn | director | +70,000 | $1.40 |
| Dec 18, 2025 | Alexander Schornstein | 10 percent owner | −690,611 | $1.37 |
| Nov 19, 2025 | James P. Flynn | director | +12,100 | $1.88 |
- Strategy
Large public digital-asset treasury and capital-markets vehicle
- SELLAS Life Sciences Group
Selective CDK9 program in AML clinical development
- Gilead Sciences
Marketed PI3Kδ therapy for relapsed CLL
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lite Strategy | $1.05 | +5.13% | $35.4M | — | — | — | — |
| Strategy | $124.16 | +0.77% | $40.75B | — | 2.9 | 81.8 | +6.9% |
| SELLAS Life Sciences Group | $13.93 | −1.66% | $2.63B | — | — | — | — |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Median | — | 9.7 | 43.9 | +8.5% |